WHO recognizes asthma as a disease of major public importance and stimulates research in to the causes of asthma to develop new control strategies and treatment techniques. Inhaled corticosteroid (ICS) used as first line preventive therapy is associated with systemic adverse events. The aim of the study was to improve patient care and therapeutic benefits by including montelukast along with ICS. The corticosteroid sparing properties of montelukast was studied and the efficacy of concomitant montelukast was evident in test group with FEVI value (2.16vs1.73) with improvement in mean day time score and mean asthma free days and reduction in ß agonist use & mean asthma exacerbation days.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : February 15, 2019